[Molecular classification of aggressive B-cell lymphoma].

Diffuse large B-cell lymphoma (DLBCL) is a clinically and biologically highly heterogeneous disease; various molecular genetic abnormalities contribute to DLBCL development. In particular, recent advances in genomics technologies have led to the discovery of unknown genetic abnormalities and gene expression patterns. Based on the identified pathophysiologies, molecular sub-classification of DLBCL has been progressing. These are important for the discovery of new therapeutic agents and the planning of clinical trials and should be recognized by clinicians as the basis of future personalized medicine.